Skip to main content

Versant backs new, medtech-focused Vensana Capital fund, launching with $225M | FierceBiotech

By September 9, 2019News
versant-capital-logo

versant-capital-logo

Vensana Capital—an independent, medtech-focused venture capital investment firm supported by Versant Ventures—has launched with a $225 million fund and ambitions to support new breakthroughs in medical devices, diagnostics and data science.

{iframe}https://www.fiercebiotech.com/medtech/versant-backs-new-medtech-focused-vensana-capital-fund-launching-225m{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.